Skip to content

Anti-pigmentation potency of Mosaic Depigmentation serum

A Single arm clinical study to evaluate the anti-pigmentation activity of Mosaic Depigmentation serum - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/099349
Enrollment
34
Registered
2025-12-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test product: Depigmentation serum: Test Product: depigmentation serum Dose: Gently use approx. 1ml of the Depigmentation Serum on the face twice a day for 6 weeks. Route of Administrat

Sponsors

Mosaic Wellness Pvt. Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male or Female with age 18-55 2) Subjects with mild pigmentation 3) Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3. Have open sores or open lesions in the treatment area(s). 4. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 5. Have participated in any interventional clinical trial in the previous 90 days. 6. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication. 7. Have not skin related issues.

Design outcomes

Primary

MeasureTime frame
1. Change in skin Gloss 2. Change in Pigmentation/melanin 3. Change in Skin Lightness 4. Change in Dark Spots 5. Change in Even Skin Tone scoreTimepoint: Day 0, 14, 28, 42

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026